bgs649
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2010 (NCT01116440)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cytochrome P450 19A1INHIBITOR
CYP19A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bgs649
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02908074 | Phase 2 | Nov 1, 2016 | Barnsley Hospital NHS Foundation Trust, Mereo BioPharma |
| NCT02730169 | Phase 2 | Apr 1, 2016 | Barnsley Hospital NHS Foundation Trust, Mereo BioPharma |
| NCT01200862 | Phase 2 | Aug 1, 2010 | Novartis |
| NCT01190475 | Phase 2 | Jul 1, 2010 | Novartis |
| NCT01116440 | Phase 2 | Apr 1, 2010 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 3 | 3 | 1 | 2010 |
| Barnsley Hospital NHS Foundation Trust | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Mereo BioPharma | For profit | 2 | 2 | 1 | 2016 |
3 organizations
Page 1 / 1